

PRVPATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

GB00/3474

REC'D 29 SEP 2000

WIPO

PCT

**Intyg
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca UK Ltd, London GB
Applicant (s)

(21) Patentansökningsnummer 9903290-6
Patent application number

(86) Ingivningsdatum 1999-09-15
Date of filing

Stockholm, 2000-08-11

För Patent- och registreringsverket
For the Patent- and Registration Office

Anita Södervall
Anita Södervall

Avgift
Fee 170:-

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

**PATENT- OCH
REGISTRERINGSVERKET**
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

PRV99-09-15

Applicant: **Astra Pharmaceuticals Ltd.**

Home Park

Kings Langley

Herts WD4 8DH

United Kingdom

Title: **NOVEL COMPOUNDS**

Reference: **F2210-1SE**

Inventors: **Barry Teobald**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

NOVEL COMPOUNDS

The present invention provides novel hydroxypyrrolidine compounds, their use as medicaments, compositions containing them and processes for their preparation.


5 Platelet adhesion and aggregation are initiating events in arterial thrombosis. Although the process of platelet adhesion to the sub-endothelial surface may have an important role to play in the repair of damaged vessel walls, the platelet aggregation that this initiates can precipitate acute thrombotic occlusion of vital vascular beds, leading to events with high morbidity such as myocardial
10 infarction and unstable angina. The success of interventions used to prevent or alleviate these conditions, such as thrombolysis and platelet-mediated occlusion or re-occlusion also compromises angioplasty.

A number of converging pathways lead to platelet aggregation. Whatever the initial stimulus, the
15 final common event is a cross-linking of platelets by binding of fibrinogen to a membrane-binding site, glycoprotein IIb/IIIa (GPIIb/IIIa). The high anti-platelet efficacy of antibodies or antagonists for GPIIb/IIIa is explained by their interference with this final common event. However, this efficacy may also explain the bleeding problems that have been observed with this class of agent. Thrombin can produce platelet aggregation largely independently of other pathways but substantial
20 quantities of thrombin are unlikely to be present without prior activation of platelets by other mechanisms. Thrombin inhibitors such as hirudin are highly effective anti-thrombotic agents, but again may produce excessive bleeding because they function as both anti-platelet and anti-coagulant agents (The TIMI 9a Investigators (1994), *Circulation* 90, pp. 1624-1630; The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994)
25 *Circulation* 90, pp. 1631-1637; Neuhaus K. L. et. al. (1994) *Circulation* 90, pp. 1638-1642).

It has been found that ADP acts as a key mediator of thrombosis. A pivotal role for ADP is supported by the fact that other agents, such as adrenaline and 5-hydroxytryptamine (5HT, serotonin) will only produce aggregation in the presence of ADP. The limited anti-thrombotic
30 efficacy of aspirin may reflect the fact that it blocks only one source of ADP which is that released in a thromboxane-dependent manner following platelet adhesion (see e.g. Antiplatelet Trialists' Collaboration (1994), *Br. Med. J.* 308, pp. 81-106; Antiplatelet Trialists' Collaboration (1994), *Br. Med. J.* 308, pp. 159-168). Aspirin has no effect on aggregation produced by other sources of ADP, such as damaged cells or ADP released under conditions of turbulent blood flow. ADP-
35 induced platelet aggregation is mediated by the P_{2T} (P_{2Y}_{ADP} or P_{2T}_{AC}) -receptor subtype uniquely located on the platelet membrane. Recently it has been shown that antagonists at this

receptor offer significant improvements over other anti-thrombotic agents. Accordingly there is a need to find $P2T$ ($P2Y_{ADP}$ or $P2T_{AC}$) antagonists as anti-thrombotic agents.

In a first aspect the invention therefore provides a compound of formula (I):



(I)

Wherein:

R^1 is H, CH_2R^5 or COR^6 ;

R^2 is alkyl or alkenyl C_{1-6} , optionally substituted by one or more groups selected from alkyl C_1 ,

5, halogen;

R^3 is cycloalkyl C_{3-8} , optionally substituted by R^7 ;

R^4 is H or alkyl C_{1-6} , optionally substituted by one or more halogens;

R^5 is H, phenyl or alkyl C_{1-6} , optionally substituted by halogen, OR^8 , phenyl;

R^6 is OR^8 or alkyl C_{1-6} , optionally substituted by one or more groups selected from halogen,

15 OR^8 , phenyl;

R^7 is phenyl, optionally substituted by one or more groups selected from alkyl C_{1-6} , halogen,

OR^8 ;

R^8 is H or alkyl C_{1-6} , optionally substituted by one or more groups selected from halogen or alkyl C_{1-6} ;

20


or a pharmaceutically acceptable salt or solvate thereof.

Compounds of the invention can form pharmaceutically acceptable salts. The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, trifluoroacetic and methanesulphonic acids.

5



Preferably the compound of formula (I) has the following stereochemistry:

10



15

(Ia)

Where $R^3 =$  R^7 the stereochemistry is preferably 

20

Particularly preferred compounds of the invention include:

[3R-[3 α ,4 β (1R*,2S*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

25

[3S-[3 α ,4 β (1S*,2R*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

[3*S*-[3 α ,4 β (1*R**, 2*S**)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;

5 [3*S*-[3 α ,4 β (1*S**, 2*R**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 α ,4 β (1*R**, 2*S**)]]-4-[7-[*N*-Methyl-*N*-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

10 [3*R*-[3 α ,4 β (1*R**, 2*S**)]]-1-Hydroxyethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol;

[3*R*-[3 α ,4 β (1*R**, 2*S**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-(phenylmethyl)-3-pyrrolidinol;


15 [3*R*-[3 α , 4 β (1*R**, 2*S**)]]-1-Acetyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol.

or pharmaceutically acceptable salts or solvates thereof.

20 According to the invention there is further provided a process for the preparation of a compound of formula (I) which comprises:

a. For compounds of formula (I) where R¹ is H, reacting a compound of formula (II)


25



wherein R^2 is as defined above and P is a protecting group, preferably t-BuOCO, with R^3R^4NH , wherein R^3 and R^4 are as defined in (I), and a base, preferably triethylamine or *N,N*-disopropylethylamine, in the presence of an inert solvent preferably acetonitrile, preferably at a temperature between 20 °C and 100 °C and optionally thereafter removing any protecting groups.

Protecting groups can be added and removed using known reaction conditions. The use of protecting groups is fully described in 'Protective Groups in Organic Chemistry', edited by J W F McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T W Greene & P G M Wutz, Wiley-Interscience (1991).


A compound of formula (II) can be prepared by diazotizing a compound of formula (III)



(III)


where R^2 and P are defined above, and where necessary other reactive groups might also be protected, with a C_{1-6} alkyl nitrite, preferably iso-amyl nitrite in the presence of an inert solvent preferably acetonitrile at 20-80 °C, or with an alkali metal nitrite, preferably sodium nitrite, under aqueous acidic conditions, preferably aqueous hydrochloric or acetic acid and preferably at a temperature between 0 °C and 20 °C.

A compound of formula (III) can be prepared by reacting a compound of formula (IV).




(IV)

wherein P is a protecting group, with a compound of formula V



(V)

- 5 wherein R^2 is as defined in formula (I) and is preferably n-propyl. The reaction is carried out in the presence of a base, preferably triethylamine or *N,N*-disopropylethylamine, in an inert solvent preferably *N,N*-dimethylformamide or n-butanol, at a temperature between 100°C and 150°C.
- 10 The preparation of the formula (IV) racemate is described in Okada et al., Chem. Pharm. Bull. (1993), 41, 132-8; the preparation of formula (IV) enantiomers is described in Schaus, et al., J. Org. Chem. (1997), 62, 4197-9; the preparation of a compound of formula V (R^2 is n-propyl) is described in EP 508687.
- 15 Compounds of formula (I) where R^2 is other than n-propyl are prepared by displacement of the sulphone group from a compound of formula (VI)



(VI)

- where R^2 is n-propyl, P, R^3 and R^4 are defined above, using either a sodium alkylthiolate ($R^2\text{SNa}$) in the presence of an inert solvent, preferably *N,N*-dimethylformamide, preferably at a temperature between 0°C and 50°C or sodium hydrosulphide (NaSH), in the presence of an inert solvent preferably *N,N*-dimethylformamide. This reaction is followed by alkylation with an alkyl halide ($R^2\text{X}$, where X is a leaving group preferably bromide or iodide), preferably at a temperature between 0°C and 50°C and optionally thereafter removing any protecting groups.
- 10 The preparation of the compound of formula (VI), where R^2 is n-propyl, is preferably carried out by reacting a compound of formula (I), where R^1 has been protected as described above, with a peracid, preferably *m*-chloroperoxybenzoic acid, in the presence of an inert chlorocarbon solvent such as dichloromethane or a mixture of dichloromethane and methanol, at a temperature between 0°C and 50°C .
- 15 b. For compounds of formula (I) where R^1 is CH_2R^5 , where R^5 is defined in formula (I), the reaction scheme outlined in a. above is followed by reductive amination using an aldehyde (R^5CHO) and a reducing agent, preferably sodium triacetoxyborohydride, and optionally thereafter removing any protecting groups. The reductive amination reaction is preferably carried out in the presence of an inert solvent preferably *N,N*-dimethylformamide, tetrahydrofuran or a mixture of acetonitrile and *N*-methylpyrrolidone and preferably at a temperature between 0°C and 50°C .
- 20

c. For compounds of formula (I) where R^1 is COR^6 , where R^6 is defined in formula (I), the reaction scheme outlined in a. above is followed by acylation using an acid halide (R^6COX) or anhydride ($(R^6CO)_2O$) or an acid (R^6CO_2H) in the presence of a suitable activating agent preferably N,N' -carbonyldiimidazole or N,N' -dicyclohexylcarbodiimide, and a base preferably triethylamine or N,N -disopropylethylamine, and optionally thereafter removing any protecting groups. The acylation is preferably carried out in the presence of an inert solvent preferably dichloromethane, chloroform or tetrahydrofuran and preferably at a temperature between $0^\circ C$ and $50^\circ C$.

10 All novel intermediates form a further aspect of the invention.

Salts of the compounds of formula (I) may be formed by reacting the free base, or a salt or a derivative thereof, with one or more equivalents of the appropriate acid (for example a hydrohalic (especially HCl), sulphuric, oxalic or phosphoric acid). The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, e.g. water, ethanol, THF or diethyl ether, which may be removed *in vacuo*, or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin. The non-toxic physiologically acceptable salts are preferred, although other salts may be useful, e.g. in isolating or purifying the product.

20 The compounds of the invention act as P_{2T} (P_{2YADP} or P_{2TAC}) receptor antagonists. Accordingly, the compounds are useful in therapy, including combination therapy, particularly they are indicated for use as: inhibitors of platelet activation, aggregation and degranulation, promoters of platelet disaggregation, anti-thrombotic agents or in the treatment or prophylaxis of unstable
25 angina, coronary revascularisation procedures including angioplasty (PTCA), myocardial infarction, perithrombolysis, primary arterial thrombotic complications of atherosclerosis such as thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease, myocardial infarction with or without thrombolysis, arterial complications due to interventions in atherosclerotic disease such as angioplasty, endarterectomy, stent placement, coronary and other
30 vascular graft surgery, thrombotic complications of surgical or mechanical damage such as tissue salvage following accidental or surgical trauma, reconstructive surgery including skin and muscle flaps, conditions with a diffuse thrombotic/platelet consumption component such as disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, haemolytic uraemic syndrome, thrombotic complications of septicaemia, adult respiratory distress syndrome, anti-phospholipid
35 syndrome, heparin-induced thrombocytopenia and pre-eclampsia/eclampsia, or venous thrombosis such as deep vein thrombosis, venoocclusive disease, haematological conditions such

as myeloproliferative disease, including thrombocythaemia, sickle cell disease; or in the prevention of mechanically-induced platelet activation *in vivo*, such as cardio-pulmonary bypass and extracorporeal membrane oxygenation (prevention of microthromboembolism), mechanically-induced platelet activation *in vitro*, such as use in the preservation of blood products, e.g. platelet concentrates, or shunt occlusion such as in renal dialysis and plasmapheresis, thrombosis secondary to vascular damage/inflammation such as vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease and organ graft rejection, conditions such as migraine, Raynaud's phenomenon, conditions in which platelets can contribute to the underlying inflammatory disease process in the vascular wall such as atheromatous plaque formation/progression, stenosis/restenosis and in other inflammatory conditions such as asthma, in which platelets and platelet-derived factors are implicated in the immunological disease process. Further indications include treatment of CNS disorders and prevention of the growth and spread of tumours.

According to the invention there is further provided the use of a compound according to the invention in the manufacture of a medicament for the treatment of the above disorders. In particular the compounds of the invention are useful for treating myocardial infarction, thrombotic stroke, transient ischaemic attacks, peripheral vascular disease and angina, especially unstable angina. The invention also provides a method of treatment of the above disorders which comprises administering to a patient suffering from such a disorder a therapeutically effective amount of a compound according to the invention.

The compounds may be administered topically, e.g. to the lung and/or the airways, in the form of solutions, suspensions, HFA aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, pills, capsules, syrups, powders or granules, or by parenteral administration in the form of sterile parenteral solutions or suspensions, by subcutaneous administration, or by rectal administration in the form of suppositories or transdermally.

The compounds of the invention may be administered on their own or as a pharmaceutical composition comprising the compound of the invention in combination with a pharmaceutically acceptable diluent, adjuvant or carrier. Particularly preferred are compositions not containing material capable of causing an adverse, e.g. an allergic, reaction.

Dry powder formulations and pressurised HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation. For inhalation the compound is desirably finely divided. The compounds of the invention may also be administered by means of a dry powder inhaler. The inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.

One possibility is to mix the finely divided compound with a carrier substance, .g. a mono-, di- or polysaccharide, a sugar alcohol or another polyol. Suitable carriers include sugars and starch. Alternatively the finely divided compound may be coated by another substance. The powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.

Another possibility is to process the finely divided powder into spheres which break up during the inhalation procedure. This spheronized powder may be filled into the drug reservoir of a multidose inhaler, e.g. that known as the Turbuhaler® in which a dosing unit meters the desired dose which is then inhaled by the patient. With this system the active compound with or without a carrier substance is delivered to the patient.

The pharmaceutical composition comprising the compound of the invention may conveniently be tablets, pills, capsules, syrups, powders or granules for oral administration; sterile parenteral or subcutaneous solutions, suspensions for parenteral administration or suppositories for rectal administration.

For oral administration the active compound may be admixed with an adjuvant or a carrier, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution, which may contain e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet may be coated with a suitable polymer dissolved either in a readily volatile organic solvent or an aqueous solvent.

For the preparation of soft gelatine capsules, the compound may be admixed with e.g. a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above mentioned excipients for tablets, e.g. lactose, saccharose, sorbitol, mannitol, starches, cellulose derivatives or gelatine. Also liquid or semisolid formulations of the drug may be filled into hard gelatine capsules.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example solutions containing the compound, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents,

flavouring agents, saccharine and carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.

The invention is illustrated by the following examples. In the examples the NMR spectra were measured on a Varian Unity Inova 300 or 400 spectrometer and the MS spectra were measured as follows: EI spectra were obtained on a VG 70-250S or Finnigan Mat Incos-XL spectrometer, FAB spectra were obtained on a VG70-250SEQ spectrometer, ESI and APCI spectra were obtained on Finnigan Mat SSQ7000 or a Micromass Platform spectrometer. Preparative HPLC separations were generally performed using a Novapak[®], Bondapak[®] or Hypersil[®] column packed with BDSC-18 reverse phase silica. Flash chromatography (indicated in the Examples as (SiO₂)) was carried out using Fisher Matrix silica, 35-70 μ m. For examples which show the presence of rotamers in the proton NMR spectra only the chemical shifts of the major rotamer are quoted.

Example 1

[3*R*-(3 α ,4 β (1*R**,2*S**))]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

a) (3*R*,4*R*)-3-[[5-Amino-6-chloro-2-(propylthio)pyrimidin-4-yl]amino]-4-hydroxy-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

Triethylamine (18.8ml) was added to a solution of (3*R*,4*R*)-4-amino-3-hydroxy-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester (prepared as described in J. Org. Chem., 1997, 62, 4197 using the (*S,S*)(salen)Cr(III)complex) (3.63g) and 4,6-dichloro-2-propylthiopyrimidine-5-amine (prepared as described in EP508687) (3.56g) and the resulting mixture was heated at 100°C for 24 hours. The excess triethylamine was removed *in vacuo* and the residue was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried and concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, dichloromethane:methanol, 97:3 as eluant) followed by titration with diethylether/isohexane to give the subtitle compound (4.16g).

MS (APCI) 404 (M+H⁺, 100%).

b) (3*R*,4*R*)-4-[7-Chloro-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-hydroxy-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

5 The product from step a) (4.1g) and iso-amyl nitrite (2.74ml) were heated under reflux in acetonitrile (20ml) for 1 hour. The reaction mixture was concentrated *in vacuo* and the residue purified by chromatography (SiO₂, ethyl acetate:isohexane, 1:4 as eluant) to afford the sub-title compound (3.32g).

10 MS (APCI) 415 (M+H⁺, 100%).

c) [3*R*-[3α,4β(1*R**,2*S**)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

15

N,N-Diisopropylethylamine (3ml) was added to a solution of the product from step b) (1.2g) and (1*R-trans*)-2-phenylcyclopropanamine, [R-(*R**, *R**)]-2,3-dihydroxybutanedioate (1:1) (prepared as described by L. A. Mitscher *et al.*, J. Med. Chem., 1986, 29, 2044) (1.23g) in dichloromethane (40ml). The reaction mixture was stirred at room temperature for 16 hours then washed with water. The organic phase was washed with dilute hydrochloric acid and
20 brine, dried and concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, dichloromethane:methanol, 99:1 as eluant) to afford the sub-title compound (1.12g).

MS (APCI) 512 (M+H⁺, 100%).

25

d) [3*R*-[3α,4β(1*R**,2*S**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

The product from step c) (0.54g) was dissolved in trifluoroacetic acid (22.5ml) and water
30 (2.5ml) and the solution stirred at room temperature for 4h. The solvents were evaporated and

the residue dried by azeotropic distillation with toluene (4x50ml) followed by methanol (50ml) to give a yellow foam. The crude product was triturated with ether (50ml) to afford a white powder that was recrystallised (ethyl acetate) to afford the title compound (0.37g) as a white solid.

MS (APCI) 412 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.5 (2H, br s), 9.47 (1H, d), 7.10-7.35 (5H, m), 6.28 (1H, d), 5.26 (1H, br m), 4.65 (1H, br s), 3.90 (2H, m), 3.52 (1H, d, AB), 3.3 (1H, m), 3.24 (1H, m), 2.8-3.0 (2H, t, AB), 2.13 (1H, m), 1.54 (1H, d, t), 1.47 (2H, sext.), 1.34 (1H, br q), 0.79 (3H, t).

Example 2

[3S-[3 α ,4 β (1S*,2R*)]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

a) (3S,4S)-3-[[5-Amino-6-chloro-2-(propylthio)pyrimidin-4-yl]amino]-4-hydroxy-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

Prepared according to the method of Example 1, step a) using (3S,4S)-4-amino-3-hydroxy-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester (prepared as described in J. Org. Chem., 1997, 62, 4197 using the (R,R)(salen)Cr(III) complex).

MS (APCI) 404/406 (M+H⁺), 404 (100%).

b) (3S,4S)-4-[7-Chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-hydroxy-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

Prepared according to the method of Example 1, step b).

MS (APCI) 315 (M+H-BOC⁺, 100%).

c) [3S-[3 α ,4 β (1S*,2R*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

5 Prepared according to the method of Example 1, step c).

MS (APCI) 512 (M+H⁺, 100%).

10 NMR δ H (d₆-DMSO) 9.40 (1H, d), 7.31-7.27 (2H, m), 7.20-7.15 (3H, m), 5.78-5.76 (1H, m), 5.11-5.06 (1H, m), 4.61-4.56 (1H, m), 3.94-3.81 (2H, m), 3.69-3.62 (1H, m), 3.30-3.18 (2H, m), 3.11-2.80 (2H, m), 2.15-2.10 (1H, m), 1.73-1.23 (13H, m), 0.80 (3H, t).

Example 3

15 [3S-[3 α ,4 β (1R*, 2S*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester

a) [3S-[3 α ,4 β (1R*, 2S*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl

20 ester

Prepared according to the method of Example 2, step c) using (1S-*trans*)-2-phenylcyclopropanamine, [S-(R*, R*)]-2,3-dihydroxybutanedioate (1:1) (prepared as described by L. A. Mitscher *et al.*, J. Med. Chem., 1986, 29, 2044).

25

MS (APCI) 512 (M+H⁺, 100%).

30 NMR δ H (d₆-DMSO) 9.40 (1H, d), 7.31-7.27 (2H, m), 7.20-7.15 (3H, m), 5.78-5.76 (1H, m), 5.11-5.06 (1H, m), 4.62-4.58 (1H, m), 3.94-3.81 (2H, m), 3.69-3.63 (1H, m), 3.30-3.18 (2H, m), 3.11-2.80 (2H, m), 2.15-2.11 (1H, m), 1.72-1.23 (13H, m), 0.80 (3H, t).

Example 4

[3S-[3 α ,4 β (1S*,2R*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

- 5 a) [3S-[3 α ,4 β (1S*,2R*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

Prepared according to the method of Example 1, step d) using the compound of Example 2, step c)

10

MS (APCI) 412 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.5 (2H, br s), 9.48 (1H, d), 7.10-7.35 (5H, m), 6.30 (1H, d), 5.26 (1H, br m), 4.64 (1H, br s), 3.9 (2H, m), 3.5 (1H, d, AB), 3.26 (1H, m), 3.24 (1H, m), 2.7-3.0 (2H, t, AB), 2.11 (1H, m), 1.55 (1H, d, t), 1.46 (2H, sext.), 1.34 (1H, br q), 0.78 (3H, t).

15

Example 5

[3R-[3 α ,4 β (1R*,2S*)]]-4-[7-[N-Methyl-N-(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

20

a) [3R-[3 α ,4 β (1R*,2S*)]]-3-Hydroxy-4-[7-[N-methyl-N-(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester.

25

N,N-Diisopropylethylamine (0.5ml) was added to a solution of the product from Example 1 step b) (0.3g) and (1R-trans)-N-methyl-2-phenylcyclopropylamine hydrochloride (prepared as described by C. Kaiser *et al*, J. Org. Chem., 1962, 27, 768-773, using (1R-trans)-2-phenylcyclopropanamine, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1) (prepared as described by L.A. Mitscher *et al*, J. Med. Chem., 1986, 29, 2044) (0.2g) in dichloromethane (20ml). The

30

reaction mixture was stirred at room temperature for 48 hours then washed with water. The organic phase was washed with dilute hydrochloric acid and brine, dried and concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, dichloromethane:methanol, 99:1 as eluant) to afford the sub-title compound (0.36g).

MS (APCI) 470 (M+H⁺, 100%).

b) [3R-[3 α ,4 β (1R*,2S*)]]-4-[7-[N-Methyl-N-(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

A solution of the product from step a) (0.36g) in 9:1 trifluoroacetic acid:water (10ml) was stirred at room temperature for 2 hours. The solvent was removed and co-evaporated with toluene (3x). The residue was dissolved in water (20ml) and ethanol (1ml) and freeze-dried for 16 hours to give the title compound (0.33g).

MS (APCI) 426 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.33 (2H, br s), 7.29 (2H, m), 7.20 (3H, m), 6.04 (1H, br s), 5.27 (1H, m), 4.72 (1H, d), 3.84-3.97 (2H, m), 3.56 (4H, m), 3.31 (1H, d), 3.06 (3H, under DMSO), 2.43 (1H, under H₂O), 1.54-1.66 (3H, m), 1.45 (1H, m), 0.94 (3H, t).

Example 6

[3R-[3 α ,4 β (1R*,2S*)]]-1-Hydroxyethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

a) [3R-[3 α ,4 β (1R*,2S*)]]-1-[2-[(1,1-Dimethylethyl)(dimethylsilyl)oxy]ethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol.

[[1,1-Dimethylethyl)dimethylsilyl]oxy]acetaldehyde (*Tet. Lett.*, 1995, 36, 6033) (0.27g) was added to a solution of the product from Example 1 step d) (0.4g) and sodium triacetoxyborohydride (0.48g) in dry tetrahydrofuran (10ml) and the mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (thrice). The combined organic phase was washed with brine, dried and concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, dichloromethane:methanol, 99:1 as eluant) to give the sub-title compound (0.2g).

MS (APCI) 570 (M+H⁺, 100%).

b) [3R-[3 α ,4 β (1R*,2S*)]]-1-Hydroxyethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol, trifluoroacetate salt

Tetrabutylammonium fluoride hydrate (0.2g) was added to a solution of the product from step a) (0.2g) in dry tetrahydrofuran (10ml) and the mixture was stirred at room temperature for 16 hours. The solvent was removed *in vacuo* and the residue was purified by chromatography (SiO₂, dichloromethane:methanol, 95:5 as eluant). Trifluoroacetic acid (22 μ l) was added to a solution of the resulting oil in diethylether (5ml) and the solid formed was collected by filtration to give the title compound (0.12g).

MS (APCI) 456 (M+H⁺, 100%).

NMR δ H (d₆-DMSO+D₂O) 7.31 (2H, m), 7.21 (3H, m), 5.36 (1H, br s), 4.87 (1H, br s), 4.18 (1H, m), 4.04 (1H, m), 3.82 (3H, m), 3.55 (1H, under H₂O), 3.45 (2H, m), 3.29 (1H, br s), 3.02 (2H, br s), 2.22 (1H, br s), 1.58 (2H, br s), 1.50 (1H, m), 1.36 (1H, m), 0.88 (3H, br s).

Example 7

[3R-[3 α ,4 β (1R*,2S*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-(phenylmethyl)-3-pyrrolidinol, trifluoroacetate salt

5 Benzaldehyde (0.1ml) was added to a solution the product from Example 1 step d) (0.26g) and sodium triacetoxyborohydride (0.32g) in dry tetrahydrofuran (10ml) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (thrice). The combined organic phase was washed with brine, dried and concentrated. Trifluoroacetic acid (20 μ l) was added to a solution of the resulting oil
10 in diethylether (5ml) and the solvent was removed *in vacuo*. The residue was dissolved in water (20ml) and ethanol (5ml) and freeze-dried for 16 hours. Purification by chromatography (HPLC, Novapak[®] C18 column, 0.1% aqueous trifluoroacetic acid:acetonitrile, gradient elution 75:25 to 0:100 over 15 minutes), followed by freeze drying gave the title compound (0.094g).

15 MS (APCI) 502 (M+H⁺, 100%).

NMR δ H (d₆-DMSO+D₂O) 7.53 (2H, d), 7.48 (3H, m), 7.31 (2H, m), 7.20 (3H, m), 5.34 (1H, m), 4.88 (1H, m), 4.48 (2H, q), 4.05 (1H, m), 3.90 (1H, m), 3.72 (1H, m), 3.41 (1H, m),
20 3.30(1H, br m), 3.01 (2H, br m), 2.21 (1H, br s), 1.50-1.56 (3H, m), 1.36 (1H, m), 0.87 (3H, br s).

Example 8

25 **[3R-[3 α ,4 β (1R*,2S*)]]-1-Acetyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol.**

A mixture the product from Example 1 step d) (0.17g), acetic anhydride (0.046ml) and pyridine (0.078ml) in dichloromethane (3ml) was stirred at room temperature under a nitrogen
30 atmosphere for 16 hours. The reaction mixture was diluted with water and extracted with

dichloromethane (twice). The combined organic phase was washed with dilute hydrochloric acid and brine, dried and concentrated *in vacuo*. The residue was purified by chromatography (SiO_2 , dichloromethane:methanol, 98:2 as eluant) followed by trituration with acetonitrile to give the title compound (0.06g).

5

MS (APCI) 454 ($\text{M}+\text{H}^+$, 100%).

NMR δH (d_6 -DMSO) 9.39 (1H, m), 7.30 (2H, m), 7.19 (3H, m), 5.77-5.86 (1H, m), 5.09-5.16 (1H, m), 4.60-4.69 (1H, m), 4.00-4.13 (1H, m), 3.91 (2H, m), 3.46, 3.68 (1H, m), 3.21 (1H, br m), 2.82-2.91 (2H, m), 2.13 (1H, m), 1.98 (3H, d), 1.34-1.54 (4H, m), 0.79 (3H, t).

10

Pharmacological data

The preparation for the assay of the P2T (P2Y_{ADP} OR P2T_{AC})-receptor agonist/antagonist activity in washed human platelets for the compounds of the invention was carried out as follows.

5 Human venous blood (100 ml) was divided equally between 3 tubes, each containing 3.2% trisodium citrate (4 ml) as anti-coagulant. The tubes were centrifuged for 15 minutes at 240G to obtain a platelet-rich plasma (PRP) to which 300 ng/ml prostacyclin was added to stabilize the platelets during the washing procedure. Red cell free PRP was obtained by centrifugation for 10
10 minutes at 125G followed by further centrifugation for 15 minutes at 640G. The supernatant was discarded and the platelet pellet resuspended in modified, Calcium Free Tyrode solution (10 ml) (CFT), composition: NaCl 137mM, NaHCO₃ 11.9mM, NaH₂PO₄ 0.4mM, KCl 2.7 mM, MgCl₂ 1.1 mM, dextrose 5.6 mM, gassed with 95% O₂/5% CO₂ and maintained at 37°C. Following addition
15 of a further 300 ng/ml PGI₂, the pooled suspension was centrifuged once more for 15 minutes at 640G. The supernatant was discarded and the platelets resuspended initially in 10 ml CFT with further CFT added to adjust the final platelet count to 2x10⁵/ml. This final suspension was stored in a 60 ml syringe at 3°C with air excluded. To allow recovery from PGI₂-inhibition of normal function, platelets were used in aggregation studies no sooner than 2 hours after final resuspension.

20 In all studies, 3 ml aliquots of platelet suspension were added to tubes containing CaCl₂ solution (60 µl of 50 mM solution with a final concentration of 1mM). Human fibrinogen (Sigma, F 4883) and 8-sulphophenyltheophylline (8-SPT which was used to block any P₁-agonist activity of compounds) were added to give final concentrations of 0.2 mg/ml (60 µl of 10 mg/ml solution of clottable protein in saline) and 300 nM (10 µl of 15 mM solution in 6% glucose), respectively.
25 Platelets or buffer as appropriate were added in a volume of 150 µl to the individual wells of a 96 well plate. All measurements were made in triplicate in platelets from each donor.

The agonist/antagonist potency was assessed as follows.

30 Aggregation responses in 96 well plates were measured using the change in absorbance given by the plate reader at 660 nm. Either a Bio-Tec Ceres 900C or a Dynatech MRX were used as the plate reader.

35 The absorbance of each well in the plate was read at 660 nm to establish a baseline figure. Saline or the appropriate solution of test compound was added to each well in a volume of 10 µl to give a final concentration of 0, 0.01, 0.1, 1, 10 or 100 mM. The plate was then shaken for 5 min on an

orbital shaker on setting 10 and the absorbance read at 660 nm. Aggregation at this point was indicative of agonist activity of the test compound. Saline or ADP (30 mM; 10 μ l of 450 mM) was then added to each well and the plate shaken for a further 5 min before reading the absorbance again at 660 nm.


5

Antagonist potency was estimated as a % inhibition of the control ADP response to obtain an IC_{50} . Compounds exemplified have pIC_{50} values of more than 5.0.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189

Claims

1. A compound of formula (I):



(I)

Wherein:

R¹ is H, CH₂R⁵ or COR⁶;

R² is alkyl or alkenyl C₁₋₆, optionally substituted by one or more groups selected from alkyl C₁₋

6, halogen;

R³ is cycloalkyl C₃₋₆, optionally substituted by R⁷;

R⁴ is H or alkyl C₁₋₆, optionally substituted by one or more halogens;

R⁵ is H, phenyl or alkyl C₁₋₆, optionally substituted by halogen, OR⁸, phenyl;

R⁶ is OR⁸ or alkyl C₁₋₆, optionally substituted by one or more groups selected from halogen,

OR⁸, phenyl;

R⁷ is phenyl, optionally substituted by one or more groups selected from alkyl C₁₋₆, halogen,


OR⁸;

R⁸ is H or alkyl C₁₋₆, optionally substituted by one or more groups selected from halogen or



alkyl C₁₋₆;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 having the following stereochemistry:



(Ia)

Where $R^3 =$  R^7 the stereochemistry is preferably  or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 or 2 in which R^1 is H, CH_2Ph , CH_2CH_2OH , or CO_2tBu .
4. A compound according to claim 1 or 2 in which R^2 is n-Pr
5. A compound according to claims 1 and 2 which is:
 - 10 [3R-[3 α ,4 β (1R*,2S*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;
 - [3S-[3 α ,4 β (1S*,2R*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;
 - 15 [3S-[3 α ,4 β (1R*,2S*)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-pyrrolidinecarboxylate, 1,1-dimethylethyl ester;
 - [3S-[3 α ,4 β (1S*,2R*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;
 - 20

[3R-[3 α ,4 β (1R*,2S*)]]-4-[7-[(N-Methyl-N-(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

5 [3R-[3 α ,4 β (1R*,2S*)]]-1-Hydroxyethyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol;

[3R-[3 α ,4 β (1R*,2S*)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-1-(phenylmethyl)-3-pyrrolidinol;

10 [3R-[3 α ,4 β (1R*,2S*)]]-1-Acetyl-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-3-pyrrolidinol.

or pharmaceutically acceptable salts or solvates thereof.

15 6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 in combination with a pharmaceutically acceptable diluent, adjuvant or carrier.

7. A compound according to any one of claims 1 to 5 for use in therapy.


20 8. A compound according to any one of claims 1 to 5 for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischaemic attacks, peripheral vascular disease and angina.

25 9. A compound according to any one of claims 1 to 5 for use in the treatment or prevention of angina.

30 10. A method of treatment of a platelet aggregation disorder which comprises administering to a patient suffering from such a disorder a therapeutically effective amount of compound according to any one of claims 1 to 5.

11. A process for the preparation of a compound of formula (I) which comprises:

a. For compounds of formula (I) where R¹ is H, reacting a compound of formula (II)



(II)

wherein R^2 is as defined in formula (I) and P is a protecting group, with R^3R^4NH , wherein R^3 and R^4 are as defined in (I), and a base and optionally thereafter removing any protecting groups.

b. For compounds of formula (I) where R^1 is CH_2R^5 , where R^5 is defined in formula (I), the reaction scheme outlined in a. above is followed by reductive amination using an aldehyde (R^5CHO) and a reducing agent.

c. For compounds of formula (I) where R^1 is COR^6 , where R^6 is defined in formula (I), the reaction scheme outlined in a. above is followed by acylation using an acid halide (R^6COX) or anhydride ($(R^6CO)_2O$) or an acid (R^6CO_2H) in the presence of a suitable activating agent.

ABSTRACT

The invention provides novel hydroxypyrrolidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100